

# Recent Systemic Antifungal Exposure and Nonsusceptible *Candida* in Hospitalized Patients, South Africa, 2012–2017

Charlotte Rabault, Liliwe Shuping, Ruth Mpembe, Vanessa Quan, Fanny Lanternier, Olivier Lortholary, Olivier Paccoud, Nelesh P. Govender, for GERMS-SA



In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 **AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at [https://www.medscape.org/qna/processor/75307?showStandAlone=true&src=prt\\_jcme\\_eid\\_mscpedu](https://www.medscape.org/qna/processor/75307?showStandAlone=true&src=prt_jcme_eid_mscpedu); and (4) view/print certificate. For CME questions, see page 2071.

NOTE: It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, trade and manufacturer names in this activity are provided in an effort to provide clarity. The use of brand or manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.

**Release date: September 17, 2025; Expiration date: September 17, 2026**

## Learning Objectives

Upon completion of this activity, participants will be able to:

- Assess patterns of antifungal sensitivity among different *Candida* species
- Evaluate the epidemiology and outcomes of *Candida* bloodstream infections
- Identify the rate of antifungal resistance in the current case series of candidemia

## CME Editor

**Dana C. Dolan, BS**, Technical Writer/Editor, Emerging Infectious Diseases. *Disclosure:* Dana C. Dolan, BS, has no relevant financial relationships.

## CME Author

**Charles P. Vega, MD**, Health Sciences Clinical Professor of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. *Disclosure:* Charles P. Vega, MD, has the following relevant financial relationships: served as a consultant or advisor for Boehringer Ingelheim; GlaxoSmithKline.

## Authors

**Charlotte Rabault, MD; Liliwe Shuping, MSc; Ruth Mpembe, BTech; Vanessa Quan, MBBCh; Fanny Lanternier, MD, PhD; Olivier Lortholary, MD, PhD; Olivier Paccoud, MD; Nelesh P. Govender, MBBCh.**

*Candida* bloodstream infections, and their increasing antifungal resistance, are a global concern. In this cross-sectional study, we analyzed 2,443 culture-confirmed candidemia cases reported in South Africa during 2012–2017 to assess the effect of previous antifungal exposure on nonsusceptible *Candida* infection. We classified cases by species resistance profile and patient's antifungal use within 14 days before infection. We found that 48% of cases were caused by nonsusceptible species, and 20% of patients had prior

antifungal exposure, mainly to fluconazole. In patients >90 days of age, prior antifungal use was significantly associated with nonsusceptible *Candida* bloodstream infection (adjusted OR 2.02, 95% CI 1.43–2.87;  $p < 0.001$ ), with species-specific effects. No such association was found in neonates and young infants, for whom hospital transmission appeared more influential. Our findings underscore the need for targeted antifungal stewardship and enhanced infection prevention to mitigate antifungal resistance in South Africa.

*Candida* bloodstream infections (BSIs) (i.e., candidemia) are among the most common invasive fungal infections globally, with an estimated 626,000 cases annually (1). Infections are associated with a substantial crude mortality rate of 35% (27%–60%) worldwide (1) and up to 44% in adults (2) and 38% in children (3) within South Africa. Since 2000, the epidemiology of *Candida* BSIs has shifted (4). *C. albicans*, which is largely fluconazole susceptible, has historically accounted for most infections, but it is now increasingly replaced by non-*albicans* *Candida* species (NAC), such as *Nakaseomyces glabratus* (formerly *C. glabrata*), that exhibit reduced susceptibility to  $\geq 1$  antifungal classes, either intrinsically or through acquisition of resistance mechanisms (5,6).

South Africa is facing a large epidemic of BSI caused by antifungal-resistant (AFR) *Candida*. *C. parapsilosis* was documented as a leading cause of candidemia since 2009; more than two thirds of tested isolates exhibited resistance to azoles (7). *C. auris*, a multidrug-resistant species, has spread rapidly to become the second most common cause of candidemia since 2020 (8,9). The exact drivers of antifungal resistance in *Candida* BSIs remain inadequately understood. Prior exposure to antifungal agents has been described as a potent driver of NAC selection in settings with low resistance prevalence (10,11), in specific populations such as in intensive care units (ICU) (12), in hematologic and oncologic wards (13,14), or through ecologic studies (15). Such exposure has also been described as contributing to acquired resistance, mainly after prolonged therapy (16,17), but might not fully explain dissemination of those last strains (18,19), which has primarily been observed during outbreaks in local or regional healthcare settings

(20–22). Most of those studies have focused on adult populations, with limited data from neonatal and pediatric populations, which account for most candidemia cases in South Africa (8).

Treatment options are currently limited to 4 systemic antifungal classes: azoles, echinocandins, polyenes, and flucytosine (23). In low- and middle-income countries (LMIC), limited access to echinocandins, newer-generation azoles, and lipid amphotericin B formulations leads to a heavy reliance on fluconazole, despite the prevailing resistance patterns (24). Consequently, the effect of AFR is greater in those settings (25), leading to a higher risk for treatment failure (26) and use of toxic drugs such as conventional amphotericin B (27). Understanding factors leading to AFR is crucial to implement prevention or mitigation strategies (28). In this study, we aimed to determine whether recent exposure to systemic antifungal drugs was associated with the occurrence of nonsusceptible *Candida* BSI among hospitalized patients at sentinel sites in South Africa.

## Materials and Methods

### Study Design and Surveillance Methods

In this cross-sectional study nested within the nationwide laboratory-based surveillance network in South Africa (GERMS-SA), we included all patients with culture-confirmed candidemia caused by any of the 6 most common *Candida* species (*C. albicans*, *N. glabratus*, *Pichia kudriavzevii* [formerly *C. krusei*], *C. auris*, *C. parapsilosis*, or *C. tropicalis*) identified in 31 hospital enhanced surveillance sites (ESS) in South Africa during January 1, 2012–December 31, 2017. GERMS-SA receives annual approvals from relevant university

Author affiliations: National Institute for Communicable Diseases, Johannesburg, South Africa (C. Rabault, L. Shuping, R. Mpembe, V. Quan, N.P. Govender); Hôpital Universitaire Necker-Enfants malades Service des Maladies Infectieuses et Tropicales Adultes, Paris, France (C. Rabault, F. Lanternier, O. Lortholary, O. Paccoud); Institut Pasteur, Paris (F. Lanternier, O. Lortholary); Université Paris Cité, Paris (F. Lanternier,

O. Lortholary, O. Paccoud); University of the Witwatersrand Johannesburg Faculty of Health Sciences, Johannesburg (N.P. Govender); University of Cape Town Faculty of Health Sciences, Western Cape, South Africa (N.P. Govender); University of Exeter MRC Centre for Medical Mycology, Exeter, UK (N.P. Govender)

DOI: <https://doi.org/10.3201/eid3110.250359>

and provincial ethics committees in South Africa. We obtained additional ethics clearance from the Human Research Ethics Committee (Medical) of the University of Witwatersrand for this substudy (no. M240625).

The GERMS-SA surveillance methodology has been thoroughly described elsewhere (7,8). In brief, diagnostic laboratories at surveillance sites were requested to report all episodes of candidemia to the National Institute for Communicable Diseases (NICD; Johannesburg, South Africa). We defined candidemia as illness in a person from whom any *Candida* species was identified from a blood culture specimen. We defined an episode as a 30-day period starting from the date of the first positive *Candida* species culture. Isolation of a new and different *Candida* species within that 30-day period, or any subsequent positive blood cultures after the 30-day period, defined a recurrent episode and a new case. We considered isolation of multiple *Candida* species within the same blood culture set to be a mixed episode. Nurse surveillance officers at ESS prospectively collected additional clinical data using standardized case report forms. The number of ESS and coverage of surveillance expanded over the study period, from 9 ESS in 2 provinces in 2012–2013 to 16 ESS in 8 provinces in 2014–2015, and finally to 16 ESS as well as non-ESS from the public and private health sectors in 2016–2017. Case definitions and methodology remained consistent throughout the 3 study periods.

### Diagnostic Laboratory Practices

We confirmed species identification using the Vitek-2 system (bioMérieux, <https://www.biomerieux.com>) or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonics, <https://www.bruker.com>). We determined MICs of all tested agents except amphotericin B (fluconazole, voriconazole, itraconazole, posaconazole, micafungin, anidulafungin, caspofungin) by using commercial microbroth dilution panels containing Alamar blue (Thermo Fisher Scientific, <https://www.thermofisher.com>), read visually after 24 hours of incubation. We used *C. parapsilosis* ATCC 22019 and *P. kudriavzevii* ATCC 6258 as quality control isolates. We determined MICs of amphotericin B by Etest (bioMérieux) on RPMI-1640 plates containing 2% glucose (DMP, <https://www.nhls.ac.za>), as recommended by the manufacturer. For isolates with acquired resistance on microbroth dilution testing, we rechecked MICs by Etest. For species other than *C. auris*, we interpreted MICs using the available Clinical and Laboratory Standards Institute clinical breakpoints (29). For *C. auris*, we interpreted MICs using the US Centers for Disease Control and Prevention tentative clinical breakpoints (30).

### Definitions

We categorized episodes of candidemia into 2 groups on the basis of their identification and susceptibility profiles. We defined nonsusceptible *Candida* isolates as those exhibiting intrinsic nonsusceptibility (*C. auris*, *P. kudriavzevii*, and *N. glabratus*) or acquired resistance to  $\geq 1$  antifungal agent, classified as intermediate (I), susceptible-dose-dependent (SDD), or resistant (R). We chose that classification in the context of antifungal access in our setting, where azoles, particularly fluconazole, are the main first-line treatment for candidemia in the public sector. For mixed episodes, we considered only the most resistant isolate. We recorded prior systemic antifungal exposure to  $\geq 1$  antifungal agent (binary variable) within 14 days before the index blood culture collection date.

### Study Population and Participant Selection

We included only episodes with  $\geq 1$  antifungal agent viable isolate processed at the NICD reference laboratory for which we had species-level identification and antifungal susceptibility test results. We excluded recurrent episodes and patients missing data on the main exposure variable from the analysis.

### Data Management and Analysis

We used a probabilistic linking method (dtalink command on Stata [31]) for patient deduplication. We described patient characteristics using Fisher exact or  $\chi^2$  tests for categorical variables and Student *t*-test or the Wilcoxon–Mann–Whitney test for continuous variables. To evaluate the effect of each confounder on the main association, we used a classical Mantel Haenszel method. We studied the association between prior antifungal exposure and nonsusceptible *Candida* BSI using a multivariable logistic regression adjusted for major confounders. Independence of individual participant outcomes could not be assumed because of observed and unobserved outbreaks leading to enhanced horizontal transmission within sites. Therefore, we integrated expected variation in candidemia risk factors and infection prevention and control measures at each ESS into the analysis and included a hospital site-level random effect regression analysis for multivariable analysis. To account for risk factors and antifungal prescription practices specific to neonates and young infants, as a prespecified effect modifier, we stratified our analysis by age group: neonates and young infants  $\leq 90$  days of age and patients  $>90$  days of age. We excluded HIV status from the final models, despite its potential as a confounding factor, because the amount of missing data was substantial ( $>40\%$ ). We considered 2-sided *p* values of  $<0.05$  significant.

We performed all statistical analyses using Stata version 18 (StataCorp LLC, <https://www.stata.com>).


## Results

### Participants

After deduplication, we noted that 8,647 cases were detected during the 6-year surveillance period, of which 4,337 were nonrecurrent episodes and had both a confirmed identification for 1 of the 6 most prevalent *Candida* species and antifungal susceptibility test results. Of those, 2,443 patients were admitted to an ESS and had a completed case investigation form (Figure). We noted differences in age category, sex, year of diagnosis, healthcare sector, province of

diagnosis, and *Candida* species between excluded and included cases (Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/31/10/25-0359-App1.pdf>).

The population studied included 1,099 (45%) patients  $\leq 90$  days of age, comprising 831 neonates ( $\leq 28$  days) and 254 young infants (29–90 days of age), and 1,342 (55%) patients  $>90$  days of age (Appendix Table 2). Overall, 94% (2,290/2,443) of patients were treated in a public-sector facility, and 71% (1,703/2,412) were admitted to an ICU. Most cases were recorded in Gauteng Province (1,397/2,443 cases [57%]) and during the 2016–2017 period (1,241/2,443 cases [51%]). Cases in neonates and young infants were reported more often than in patients  $>90$  days of age during 2014–2015 (353/1,099 [32%] vs. 242/1,342 [18%];



**Figure.** Flowchart of the selection process for 2,443 cases of candidemia from a 6-year surveillance period for secondary data analysis of recent systemic antifungal exposure and nonsusceptible *Candida* in hospitalized patients, South Africa, 2012–2017. Common *Candida* species were *C. albicans*, *C. parapsilosis*, *Nakaseomyces glabratus* (formerly *C. glabrata*), *C. auris*, *C. tropicalis*, and *Pichia kudriavzevii* (formerly *C. krusei*). CRF, case report form; ESS, enhanced surveillance site.

$p < 0.001$ ), in Gauteng Province (681/1,099 [62%] vs. 715/1,342 [53%];  $p < 0.001$ ), and in the public sector (1,094/1,099 [99%] vs. 1,194/1,342 [89%];  $p < 0.001$ ). Neonates and young infants were also more often hospitalized in an ICU (960/1,089 [88%] vs. 742/1,321 [56%];  $p < 0.001$ ) and had a longer median hospital stay before infection onset (median [IQR] 14 [9–22] vs. 11 [4–26] days;  $p < 0.001$ ) but less frequently had a central venous catheter in situ (551/1,078 [51%] vs. 742/1,321 [56%];  $p = 0.001$ ) or total parenteral nutrition administered (211/1,033 [20%] vs. 958/1,308 [24%];  $p = 0.05$ ).

### Prior Antifungal Exposure and Nonsusceptible *Candida* sp.

Overall, recent exposure to a systemic antifungal drug was recorded in 482/2,443 episodes (20%), in a larger proportion of neonates and young infants (272/1,099 [25%]) than older patients (210/1,342 [16%];  $p < 0.001$ ). The most prescribed agent was fluconazole (340/482 [71%]), in similar proportions in the 2 age groups (196/272 [72%] in neonates and infants vs. 144/210 [69%] in older patients;  $p = 0.41$ ), followed by amphotericin B deoxycholate (AmBD) (106/482 [22%]), in a higher proportion of neonates and young infants than patients >90 days of age (75/272 [28%] vs. 31/210 [15%];  $p = 0.001$ ). Echinocandins were prescribed for 48 patients, 5/272 (92%) for neonates and young infants versus 43/210 (20%) for patients >90 days of age ( $p < 0.001$ ). Exposure to multiple agents was recorded in 12% of patients ( $n = 60$ ), mainly as a fluconazole and AmBD combination (Table 1; Appendix Table 3).

Of the 2,443 culture-confirmed candidemia cases, 1,165 were classified as nonsusceptible (48%), including 542 (47%) intrinsically nonsusceptible (*N. glabratus* 27%, *C. auris* 7%, *P. kudriavzevii* 13%) and 623 (53%) with acquired resistance (fluconazole-resistant *C. parapsilosis* 51%, fluconazole-resistant *C. albicans* 1%) (Appendix Table 6). Nonsusceptible *Candida* cases were found in a higher proportion of neonates and young infants than patients >90 days of age (594/1,099 [54%] vs. 772/1,342 [43%];  $p < 0.001$ ).

### Effect of Prior Exposure to Antifungals on Nonsusceptible *Candida* BSI

The unadjusted odds ratio (OR) of nonsusceptible *Candida* candidemia among previously exposed neonates and young infants was 1.39 (95% CI 1.05–1.84) times higher than those nonexposed (Appendix Table 4). After adjusting for hospital site, age, sex, time period, province, type of delivery, and birthweight, OR decreased to 1.06 (95% CI 0.75–1.49) (Table 2). The final model revealed a strong cluster effect; differences between hospitals accounted for 14% of the variability

in the occurrence of nonsusceptible *Candida* BSI (intra-cluster correlation coefficient = 0.14;  $p < 0.001$ ).

The unadjusted OR of nonsusceptible *Candida* BSI among previously exposed older patients was 2.23 (95% CI 1.66–3.01) times higher than those nonexposed (Appendix Table 5). After adjusting for hospital site, age, sex, time-period, province, ICU admission and healthcare sector, OR remained at 2.02 (95% CI 1.43–2.87) times higher in patients with a prior exposure compared with those without prior exposure (Table 2). We observed no meaningful cluster effect in the final model (intracluster correlation coefficient <1%;  $p = 0.5$ ).

Among older patients, we observed an increased risk for nonsusceptible *Candida* BSI for those with prior exposure to azoles (unadjusted OR 1.89 [95% CI 1.35–2.64]) and echinocandins (unadjusted OR 6.75 [95% CI 3.10–14.69]) but not after prior exposure to AmBD (OR 1.87 [0.91–3.84]) (Appendix Table 8). Risks remained similar for each class after exclusion of cases with multiagent exposure (data not shown). We compared cases with and without prior exposure to azole; cases with recorded prior exposure to azole had a lower percentage of *C. albicans* (42/151 [28%]) than those without prior exposure (518/1,101 [47%];  $p < 0.001$ ). We also noted an increase in *C. parapsilosis* in cases with prior azole exposure (54/151 [36%]) than cases without prior exposure (245/1,101 [22%];  $p < 0.001$ ) (Table 3). We observed similar change in distribution after echinocandins exposure compared with no prior exposure for *C. albicans* (4/41 [10%] vs. 518/1,101 [47%];  $p < 0.001$ ) and *C. parapsilosis* (24/41 [59%] vs. 245/1,101 [22%];  $p < 0.001$ ). The proportion of *C. auris* cases was statistically higher after azole prior exposure (16/151 [11%] vs. 44/1,101 [4%];  $p = 0.002$ ) than that of cases without prior exposure. Among *C. parapsilosis* cases, the proportion of fluconazole-nonsusceptible isolates significantly increased after exposure to echinocandins (22/24 [92%] vs. 121/245 [49%];  $p < 0.001$ ), but not after azole exposure (32/54 [59%] vs. 121/245 [49%];  $p = 0.19$ ), compared with cases without exposure recorded.

### Discussion

In a high AFR prevalence setting, we found that prior systemic antifungal exposure was independently associated with nonsusceptible *Candida* BSI in patients >90 days of age, but not among neonates and young infants ( $\leq 90$  days of age). Conversely, we observed a significant cluster effect exclusively among neonates and young infants, suggesting that the occurrence of nonsusceptible *Candida* BSIs was not independent in this population. Furthermore, in the older age group, the effect of prior antifungal exposure was drug- and species-specific; we

observed a relatively higher proportion of *C. parapsilosis* and *C. auris* cases after azole and echinocandin preexposure, including a higher proportion of fluconazole-resistant *C. parapsilosis*, compared with cases without recorded prior antifungal exposure.

Previous studies showing an association between prior antifungal exposure and nonsusceptible *Candida*

BSI in adults used heterogeneous definitions and often focused on specific antifungal-species combinations. A surveillance-based study in France that included 2,441 candidemia episodes showed that prior exposure to fluconazole within the previous 30 days was associated with increased odds (OR 2.17 [95% CI 1.51–3.13]) of candidemia caused by species with

**Table 1.** Baseline characteristics by prior exposure to antifungal drugs in patients >90 days of age with culture-confirmed candidemia at sentinel hospitals, South Africa, 2012–2017\*

Characteristic	No prior exposure, n = 1,132	Prior exposure, n = 210	All patients, N = 1,342	p value
Median age, y (IQR)	35 (8–55)	33 (3–54)	34 (8–55)	0.16†
Age group			1,342	
Older infants, 90 d–1 y	112 (10)	31 (15)	143	0.071
Children and adolescents, >1 y–17 y	198 (17)	40 (19)	238	
Adults, 18 y–64 y	663 (59)	105 (50)	768	
Elderly, ≥65 y	159 (14)	34 (16)	193	
Sex			1,341	
F	531 (47)	91 (43)	622	0.335
M	600 (53)	119 (57)	719	
Year of diagnosis			1,342	
2012–2013	288 (25)	63 (30)	351	<0.001
2014–2015	215 (19)	27 (13)	242	
2016	307 (27)	37 (18)	344	
2017	322 (28)	83 (40)	405	
Province§			1,342	
Gauteng	554 (49)	74 (35)	628	<0.001
Other	578 (51)	136 (65)	714	
Healthcare sector			1,342	
Private	99 (9)	49 (23)	148	<0.001
Public	1,033 (91)	161 (77)	1,194	
Prior hospitalization (≤90 d)¶			1,328	
No	251 (22)	35 (17)	286	
Yes	869 (76)	173 (83)	1,042	
ICU admission			1,321	
No	511 (46)	68 (33)	579	<0.001
Yes	601 (54)	141 (67)	742	
Hospital stay before infection onset, d			1,309	
Median (IQR)	10 (3–22)	23 (12–41)	11 (4–26)	<0.001†
≤2	270 (25)	7 (3)	277	<0.001‡
3–7	191 (17)	23 (11)	214	
8–14	227 (21)	37 (18)	264	
15–21	129 (12)	31 (15)	160	
≥22	285 (26)	109 (53)	394	
Systemic antimicrobial drug use			1,081	
No	342 (30)	31 (15)	373	<0.001
Yes	781 (70)	177 (85)	958	
Mechanical ventilation			1,316	
No	749 (68)	126 (61)	875	0.049
Yes	359 (32)	82 (39)	441	
CVC in situ			1,314	
No	505 (46)	51 (25)	556	<0.001
Yes	603 (54)	155 (75)	758	
TPN			1,308	
No	876 (79)	120 (59)	996	<0.001
Yes	230 (21)	82 (41)	312	
HIV status			771	
Seronegative	386 (59)	78 (68)	464	0.069
Seropositive	270 (41)	37 (32)	307	

\*Values are no. (%) except as indicated. p value determined by Pearson  $\chi^2$  test except as indicated. Numbers for each category indicate no. patients for whom that information was available. Prior antifungal exposure was ≤14 d before blood culture collection. CVC, central venous catheter; ICU, intensive care unit; TPN, total parenteral nutrition.

†p value determined by Wilcoxon rank-sum test.

‡p value determined by Fisher exact test.

§Other province includes Limpopo, Mpumalanga, KwaZulu-Natal, Free State, North West, Northern Cape, Western Cape, Eastern Cape Province.

¶Prior hospital admission was recorded within the previous 90 d before current admission.

**Table 2.** Random-effect multivariable logistic regression analysis of the effect of prior exposure to antifungal drugs on nonsusceptible *Candida* bloodstream infections among patients with culture-confirmed candidemia, South Africa, 2012–2017\*

Variable	<90 d of age†		>90 days of age‡	
	Summary aOR (95% CI) for nonsusceptible <i>Candida</i> spp.	Wald p value	Summary aOR (95% CI) for nonsusceptible <i>Candida</i> spp.	Wald p value
Prior antifungal exposure				
No	Referent		Referent	
Yes	1.06 (0.75–1.49)	0.73	2.02 (1.43–2.87)	<0.001
Age group				
Neonates, ≤28 d	Referent		NA	
Young infants, 29 d–90 d	0.79 (0.53–1.16)	0.23	NA	
Older infants, >90 d–1 y	NA		Referent	
Children–adolescents, >1 y–17 y	NA		0.95 (0.58–1.56)	0.84
Adults, 18 y–64 y	NA		1.92 (1.26–2.91)	0.002
Elderly, ≥65 y	NA		2.84 (1.70–4.74)	<0.001
Sex				
F	Referent		Referent	
M	1.11 (0.84–1.47)	0.36	1.03 (0.81–1.32)	0.47
Year		0.02		
2012–2013	Referent		Referent	
2014–2015	1.97 (1.15–3.38)	0.01	1.06 (0.71–1.58)	0.77
2016	1.47 (0.92–2.32)	0.1	1.65 (1.18–2.32)	0.004
2017	1.82 (1.16–2.84)	0.009	1.49 (1.07–2.08)	0.02
Province				
Other	Referent		Referent	
Gauteng	2.93 (1.21–7.14)	0.01	1.64 (1.25–2.14)	<0.001
ICU admission				
No	NA		Referent	
Yes	NA		1.95 (1.51–2.54)	<0.001
Healthcare sector				
Private	NA		Referent	
Public	NA		0.36 (0.21–0.60)	<0.001
Hospital stay before infection onset, d				
≤2	Referent		Referent	
3–7	1.47 (0.78–2.80)	0.24	0.71 (0.47–1.05)	0.09
8–14	1.86 (1.06–3.28)	0.03	0.77 (0.53–1.13)	0.19
15–21	2.41 (1.33–4.39)	0.004	0.79 (0.51–1.23)	0.29
≥22	2.53 (1.38–4.64)	0.003	0.98 (0.69–1.40)	0.90
Type of delivery				
Cesarean section	Referent		NA	
Vaginal delivery	0.75 (0.56–1.00)	0.05	NA	
Birthweight		0.02		
NBW, ≥2,500 g	Referent		NA	
LBW, <2,500 g	1.32 (0.86–2.02)	0.21	NA	
VLBW, <1,500 g	1.49 (0.98–2.26)	0.06	NA	
ELBW, <1,000 g	1.82 (1.11–2.97)	0.018	NA	

\*aOR, adjusted odds ratio; ELBW, extremely low birthweight; ICU, intensive care unit; LBW, low birthweight; NA, not applicable; NBW, normal birthweight; VLBW, very low birthweight.

†23 clusters, mean observations per group = 42.3 (range 1–296); intracluster correlation coefficient = 0.14;  $p < 0.001$ .

‡31 clusters, mean observations per group = 42.5 (range 1–166); intracluster correlation coefficient <0.0001;  $p = 0.5$ .

intrinsically reduced fluconazole susceptibility (mainly *N. glabratus* and *P. kudriavzevii*), whereas caspofungin preexposure was responsible for a relative increase in cases of *C. parapsilosis*, *N. glabratus*, and *P. kudriavzevii* compared with *C. albicans* (11). A study focusing on prior fluconazole exposure found an increased risk ratio of 4.47 (95% CI 2.12–9.43) of NAC BSI (10). Another study found that prior exposure to any type of antifungal agent was associated with an increased risk for fluconazole nonsusceptible *Candida* isolate (32). However, most of those studies included <400 episodes; few had >13% of *C. parapsilosis* compared with other species and almost no acquired resistance. Conversely, Shorr et al. (33) did not find an effect

of prior exposure to fluconazole but used a broader definition of prior exposure (within the last 90 days) which might have diluted the effect. Blanchard et al. (34) found a significant positive association between prior exposure to echinocandins and reduced susceptibility to echinocandins in *Candida* spp. (OR 5.25; 95% CI 1.68–16.35). In this study, we used a broad definition of AFR taking into account both intrinsic and acquired resistance; acquired resistance increased recently, particularly in South Africa (6,35). Indeed, acquired resistance accounted for more than half of nonsusceptible episodes overall, largely because of fluconazole-resistant *C. parapsilosis* (95%). Although we also sought to assess echinocandin

resistance, most of the nonsusceptibility patterns encountered in our study concerned azole resistance, and all echinocandin nonsusceptibility was detected among fluconazole-intrinsic resistance species. This is particularly worrisome when considering that fluconazole is one of the only accessible antifungal agents, along with amphotericin B deoxycholate, in the public sector, which covers ≈80% of the South Africa population. The low prevalence of echinocandin resistance observed can be linked to the relatively recent access to this antifungal class in the country; at the time of our study, it was available almost exclusively in the private sector. Similar to previous studies, we found a specific selection of *C. parapsilosis* after exposure to echinocandins, which can be explained by the intrinsically higher MICs of *C. parapsilosis* to echinocandins caused by a polymorphism in the *FKS* gene (11,36). The increased risk for *C. parapsilosis* after prior azole exposure was unexpected, particularly given the lack of observed differences between fluconazole-susceptible and -nonsusceptible isolates. Consistent with data from Vallabhaneni et al. (18), in which 59% of nonsusceptible *N. glabratus* cases had no known prior echinocandin exposure, the substantial proportion of nonsusceptible *Candida* BSI episodes without reported prior antifungal exposure suggests that additional factors may be contributing to antifungal resistance.

We found no association between prior antifungal exposure and nonsusceptible *Candida* BSI among neonates and young infants. However, we observed a cluster effect that was not detected among patients >90 days of age. This finding suggests horizontal transmission during observed or unobserved outbreaks as the main mechanism of acquisition of nonsusceptible *Candida* strains in that population. Indeed, during the study period, the NICD investigated several large outbreaks of resistant *Candida* BSI in neonatal units (37). Studies focusing on the effect of antifungal prophylaxis on deaths in low-birthweight

neonates did not identify an increased risk for non-susceptible *Candida* strains (38).

Furthermore, we hypothesized that the differential impact of prior antifungal exposure could be attributed to a distinct baseline epidemiology with a higher proportion of *C. parapsilosis* and *P. kudriavzevii* in neonates and young infants. Therefore, the influence of prior exposure might be less pronounced compared with horizontal transmission. Most *P. kudriavzevii* isolates were linked to 2 outbreaks in a single neonatal unit in Gauteng Province during 2012–2015, in which overcrowding and suboptimal infection prevention and control practices were suggested as contributing factors despite the absence of a common environmental source (8). Since 2020, reports documenting the spread of *C. parapsilosis* clones in ICUs in the absence of prior antifungal exposure have increased (20); they were linked to invasive devices and found on healthcare workers’ hands (39). Furthermore, a specific clone of *C. parapsilosis* with acquired resistance to fluconazole, related to the *ERG11p* Y132F mutation, has been described globally (21,40) and in Gauteng Province (41); it is associated with persistent strains in the environment (21,42). Finally, the predominant use of polyenes as first-line treatment over azoles in the neonate population might also help explain the absence of observed resistance selection (3,43).

A limitation of this study is that it was not specifically designed to examine the association between prior antifungal exposure and nonsusceptible *Candida* BSI. We collected data on prior antifungal exposure using a binary question, completed by the type of antifungals but without details on indication (prophylaxis, preemptive, or empiric treatment), dosage, or length of exposure. Therefore, we cannot exclude the possibility that some of the recorded prior antifungal exposures were actually empiric or preemptive treatments, introducing a potential reverse causality

**Table 3.** Comparison of distribution of *Candida* isolates in patients ≥90 d of age (n = 1,301) with and without prior antifungal exposure, South Africa, 2012–2017\*

Isolate	No prior exposure, n = 1,101	Prior exposure					
		To azoles, n = 151	p value	To echinocandins, n = 41	p value	To amphotericin B, n = 28	p value
<i>C. albicans</i>	518 (47)	42 (28)	<0.001	4 (10)	<0.001	6 (21)	ND
<i>Nakaseomyces glabratus</i>	202 (18)	20 (13)	0.09	1 (2)	ND	1 (3)	ND
<i>C. auris</i>	44 (4)	16 (10)	<0.001	10 (24)	ND	9 (32)	ND
<i>C. parapsilosis</i>	245 (22)	54 (36)	<0.001	24 (59)	<0.001	8 (29)	ND
FLU-R	121 (11)	32 (21)	0.19	22 (54)	<0.001	2 (7)	ND
FLU-S	124 (11)	22 (15)	ND	2 (5)	ND	6 (21)	ND
<i>C. tropicalis</i>	57 (5)	8 (5)	0.97	2 (5)	ND	2 (7)	ND
<i>Pichia kudriavzevii</i>	34 (3)	11 (7)	0.005	0 (0)	ND	2 (7)	ND

\*Values are no. (%) except as indicated. Cases with multiple exposures or mixed episodes are excluded. p values derived by Fisher exact test when validation conditions were met. FLU-R, fluconazole nonsusceptible; FLU-S, fluconazole susceptible; ND, not determined because of the lack of verification of the assumptions required for the statistical tests.

bias. Our analysis was limited to antifungal exposure within the 14 days before the index culture, because of the structure of the case report forms. Further analyses exploring the effect of earlier exposures are warranted, particularly because a previous study (44) reported a higher risk for *N. glabratus* and *P. kudriavzevii* infections after >7 days of prior antifungal treatment compared with shorter treatment durations. Selection bias might be another limitation; we excluded 69% of cases diagnosed at sentinel hospitals because of missing data. Consequently, compared with the overall epidemiology of candidemia in the country, our sample included higher proportions of patients <18 years of age; cases caused by *C. albicans*, *C. tropicalis*, and *P. kudriavzevii*; cases from provinces other than Gauteng; and cases hospitalized in the public sector. The lack of a cluster effect observed in the older population may be attributed to the level (i.e., hospital facility) selected for the random effect; specifically, horizontal transmission appears to occur more frequently within wards than at the facility level. We excluded recurrent episodes from our analysis to avoid autocorrelation bias. However, we acknowledge that those episodes represent high-risk clinical scenarios for antifungal resistance. Dedicated analyses focusing on recurrent episodes are warranted and would contribute valuable insights into the role of prior antifungal exposure in the development of resistance. Finally, data regarding underlying conditions such as diabetes mellitus or immunocompromised status were poorly collected, resulting in residual confounding. We did not observe a change in point estimate for the main exposure effect in a smaller dataset comprising HIV status data (Appendix Table 9). Although those limitations may affect the generalizability of our findings, the large number of patients in our study provides important insights into potential mechanisms underlying AFR emergence and spread in South Africa.

Prior exposure to systemic antifungals appears to be a significant driver of nonsusceptible *Candida* BSI in patients >90 days of age. However, such exposure might not fully account for the epidemiologic patterns observed among neonates, where horizontal transmission may predominate. Neonates and young infants appear to be at particularly high risk of AFR in South Africa; specific studies should focus on that population. Finally, the implementation of antifungal stewardship programs must be accompanied by effective infection prevention and control policies to comprehensively address the large and complex issue of AFR in South Africa.

Members of GERMS-SA (2012–2017): John Black, Vanessa Pearce (Eastern Cape Province); Masego Moncho, Motlatji Maloba (Free State Province); Caroline Maluleka, Charl Verwey, Charles Feldman, Colin Menezes, David Moore, Gary Reubenson, Jeannette Wadula, Merika Tsitsi, Maphoshane Nchabeleng, Nicolette du Plessis, Nontombi Mbelle, Nontuthuko Maningi, Prudence Ive, Theunis Avenant, Trusha Nana, Vindana Chibabhai (Gauteng Province); Adhil Maharj, Fathima Naby, Halima Dawood, Khine Swe Swe Han, Koleka Mlisana, Lisha Sookan, Nomonde Dlamini, Praksha Ramjathan, Prasha Mahabeer, Romola Naidoo, Sumayya Haffeejee, Surendra Sirkar (KwaZulu-Natal Province); Ken Hamese, Ngoaka Sibiyi, Ruth Lekalakala (Limpopo Province); Greta Hoyland, Sindi Ntuli (Mpumalanga Province); Pieter Jooste (Northern Cape Province); Ebrahim Variava, Ignatius Khantsi (North West Province); Adrian Brink, Elizabeth Prentice, Kessendri Reddy, Andrew Whitelaw (Western Cape Province); Ebrahim Hoosien, Inge Zietsman, Terry Marshall, Xoliswa Poswa (AMPATH); Chetna Govind, Juanita Smit, Keshree Pillay, Sharona Seetharam, Victoria Howell (LANCET); Catherine Samuel, Marthinus Senekal (PathCare); Andries Dreyer, Khatija Ahmed, Louis Marcus, Warren Lowman (Vermaak and Vennote); Anne von Gottberg, Anthony Smith, Azwifarwi Mathunjwa, Cecilia Miller, Charlotte Sriruttan, Cheryl Cohen, Desiree du Plessis, Erika van Schalkwyk, Farzana Ismail, Frans Radebe, Gillian Hunt, Husna Ismail, Jacqueline Weyer, Jackie Kleynhans, Jenny Rossouw, John Frean, Joy Ebonwu, Judith Mwansa-Kambafwile, Juno Thomas, Kerrigan McCarthy, Liliwe Shuping, Linda de Gouveia, Linda Erasmus, Lynn Morris, Lucille Blumberg, Marshagne Smith, Martha Makgoba, Mignon du Plessis, Mimmy Ngomane, Myra Moremi, Nazir Ismail, Nelesh Govender, Neo Legare, Nicola Page, Nombulelo Hoho, Ntsieni Ramalwa, Olga Perovic, Portia Mutevedzi, Ranmini Kularatne, Rudzani Mathebula, Ruth Mpembe, Sibongile Walaza, Sunnieboy Njikhlo, Susan Meiring, Tiisetso Lebaka, Vanessa Quan, Wendy Ngubane, Amanda Shilubane, Gloria Thokozile Zulu, Ivy Rukasha, Lerato Qoza, Mabatho Mhlana, Manqoba Rodney Shandu, Mbali Dube, Nozuko Blasich, Phelly Matlapeng, Serisha Naicker, Sydney Mogokotleng, Tsidiso Maphanga, Daniel Desanto, Ernest Tsotetsi, Greg Greene (National Institute for Communicable Diseases).

C.R. received a research grant provided by the Société de Pathologie Infectieuse en Langue Française and by the Assistance Public des Hôpitaux de Paris. N.P.G. was supported by the National Institute for Health and Care Research (grant nos. NIHR134342 and NIHR303140) with UK international development funding from the UK government to support global health research. The views expressed are

those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

The authors followed STROBE guidelines in writing this article.

Author contributions: conceptualization: C.R., O.P., N.P.G.; methodology: C.R., L.S., R.M., F.L., O.L., O.P., N.P.G.; data curation: V.Q.; original draft: C.R.; review and editing: L.S., R.M., V.Q., F.L., O.L., O.P., N.P.G.

## About the Author

Dr. Rabault is an infectious diseases resident at Necker Hospital, Paris, France, and an epidemiologist master's degree student at NICD, Johannesburg, South Africa. Her primary interests include fungal infections, infectious disease epidemiology, and antimicrobial resistance.

## References

- Denning DW. Global incidence and mortality of severe fungal disease. *Lancet Infect Dis*. 2024;24:e428–38. [https://doi.org/10.1016/S1473-3099\(23\)00692-8](https://doi.org/10.1016/S1473-3099(23)00692-8)
- Govender NP, Todd J, Nel J, Mer M, Karstaedt A, Cohen C, et al. HIV infection as risk factor for death among hospitalized persons with candidemia, South Africa, 2012–2017. *Emerg Infect Dis*. 2021;27:1607–15.
- Shuping L, Mpembe R, Mhlanga M, Naicker SD, Maphanga TG, Tsotetsi E, et al. for GERMS-SA. Epidemiology of culture-confirmed candidemia among hospitalized children in South Africa, 2012–2017. *Pediatr Infect Dis J*. 2021;40:730–7. <https://doi.org/10.1097/INF.0000000000003151>
- Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. *J Antimicrob Chemother*. 2018;73(suppl\_1):i4–13. <https://doi.org/10.1093/jac/dkx444>
- Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant *Candida auris* on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. *Clin Infect Dis*. 2017;64:134–40. <https://doi.org/10.1093/cid/ciw691>
- Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY Antifungal Surveillance Program: results for *Candida* species from 1997–2016. *Open Forum Infect Dis*. 2019;6(Suppl 1):S79–94. <https://doi.org/10.1093/ofid/ofy358>
- Govender NP, Patel J, Magobo RE, Naicker S, Wadula J, Whitelaw A, et al.; TRAC-South Africa group. Emergence of azole-resistant *Candida parapsilosis* causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa. *J Antimicrob Chemother*. 2016;71:1994–2004. <https://doi.org/10.1093/jac/dkw091>
- van Schalkwyk E, Mpembe RS, Thomas J, Shuping L, Ismail H, Lowman W, et al. GERMS-SA. Epidemiologic shift in candidemia driven by *Candida auris*, South Africa, 2016–2017. *Emerg Infect Dis*. 2019;25:1698–707. <https://doi.org/10.3201/eid2509.190040>
- Govender NP, Magobo RE, Mpembe R, Mhlanga M, Matlapeng P, Corcoran C, et al. *Candida auris* in South Africa, 2012–2016. *Emerg Infect Dis*. 2018;24:2036–40. <https://doi.org/10.3201/eid2411.180368>
- Rodríguez D, Almirante B, Cuenca-Estrella M, Rodríguez-Tudela JL, Mensa J, Ayats J, et al.; Barcelona Candidemia Project Study Group. Predictors of candidaemia caused by non-*albicans* *Candida* species: results of a population-based surveillance in Barcelona, Spain. *Clin Microbiol Infect*. 2010;16:1676–82. <https://doi.org/10.1111/j.1469-0691.2010.03208.x>
- Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. *Antimicrob Agents Chemother*. 2011;55:532–8. <https://doi.org/10.1128/AAC.01128-10>
- Bailly S, Maubon D, Fournier P, Pelloux H, Schwebel C, Chapuis C, et al. Impact of antifungal prescription on relative distribution and susceptibility of *Candida* spp. – trends over 10 years. *J Infect*. 2016;72:103–11. <https://doi.org/10.1016/j.jinf.2015.09.041>
- Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in *Candida krusei* infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. *N Engl J Med*. 1991;325:1274–7. <https://doi.org/10.1056/NEJM199110313251803>
- Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al.; Australian Candidemia Study, Australasian Society for Infectious Diseases. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. *J Antimicrob Chemother*. 2010;65:1042–51. <https://doi.org/10.1093/jac/dkq053>
- Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjalldgaard P, Knudsen JD, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. *Clin Microbiol Infect*. 2013;19:e343–53. <https://doi.org/10.1111/1469-0691.12212>
- Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in *Candida* species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. *J Antimicrob Chemother*. 1995;35:103–14. <https://doi.org/10.1093/jac/35.1.103>
- Siopi M, Papadopoulos A, Spiliopoulou A, Paliogianni F, Abou-Chakra N, Arendrup MC, et al. Pan-echinocandin resistant *C. parapsilosis* harboring an F652S Fks1 alteration in a patient with prolonged echinocandin therapy. *J Fungi (Basel)*. 2022;8:931. <https://doi.org/10.3390/jof8090931>
- Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs ZG, et al. Epidemiology and risk factors for echinocandin nonsusceptible *Candida glabrata* bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008–2014. *Open Forum Infect Dis*. 2015;2:ofv163. <https://doi.org/10.1093/ofid/ofv163>
- Mencarini J, Mantengoli E, Tofani L, Riccobono E, Fornaini R, Bartalesi F, et al. Evaluation of candidemia and antifungal consumption in a large tertiary care Italian hospital over a 12-year period. *Infection*. 2018;46:469–76. <https://doi.org/10.1007/s15010-018-1139-z>
- Thomaz DY, Del Negro GMB, Ribeiro LB, da Silva M, Carvalho GOMH, Camargo CH, et al. A Brazilian interhospital candidemia outbreak caused by fluconazole-resistant *Candida parapsilosis* in the COVID-19 era. *J Fungi (Basel)*. 2022;8:100. <https://doi.org/10.3390/jof8020100>
- Presente S, Bonnal C, Normand AC, Gaudonnet Y, Fekkar A, Timsit JF, et al. Hospital clonal outbreak of fluconazole-resistant *Candida parapsilosis* harboring the Y132F ERG11p substitution in a French intensive care unit. *Antimicrob Agents Chemother*. 2023;67:e01130–22. <https://doi.org/10.1128/aac.01130-22>

22. Zhou ZL, Tseng KY, Chen YZ, Tsai DJ, Wu CJ, Chen YC, et al. Genetic relatedness among azole-resistant *Candida tropicalis* clinical strains in Taiwan from 2014 to 2018. *Int J Antimicrob Agents*. 2022;59:106592. <https://doi.org/10.1016/j.ijantimicag.2022.106592>
23. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016;62:e1–50. <https://doi.org/10.1093/cid/civ933>
24. Pathadka S, Yan VKC, Neoh CF, Al-Badriyeh D, Kong DCM, Slavin MA, et al. Global consumption trend of antifungal agents in humans from 2008 to 2018: data from 65 middle- and high-income countries. *Drugs*. 2022;82:1193–205. <https://doi.org/10.1007/s40265-022-01751-x>
25. Kaur H, Chakrabarti A. Strategies to reduce mortality in adult and neonatal candidemia in developing countries. *J Fungi (Basel)*. 2017;3:41. <https://doi.org/10.3390/jof3030041>
26. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in *Candida glabrata*: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. *Clin Infect Dis*. 2013;56:1724–32. <https://doi.org/10.1093/cid/cit136>
27. Driemeyer C, Falci DR, Oladele RO, Bongomin F, Ocansey BK, Govender NP, et al. The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. *Lancet Microbe*. 2022;3:e464–70. [https://doi.org/10.1016/S2666-5247\(21\)00190-7](https://doi.org/10.1016/S2666-5247(21)00190-7)
28. Muñoz P, Bouza E. COMIC (Collaboration Group on Mycosis) study group. The current treatment landscape: the need for antifungal stewardship programmes. *J Antimicrob Chemother*. 2016;71(suppl 2):ii5–12. <https://doi.org/10.1093/jac/dkw391>
29. Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts, 3rd ed. Supplement M27M44S. Wayne (PA): The Institute; 2022.
30. Centers for Disease Control and Prevention. Antifungal susceptibility testing for *C. auris*. 2024 [cited 2024 Jun 12]. <https://www.cdc.gov/candida-auris/hcp/laboratories/antifungal-susceptibility-testing.html>
31. Kränker K. dtalink: Faster probabilistic record linking and deduplication methods in Stata for large data files. Presented at: 2018 Stata Conference; Columbus, OH, USA; 2018 Jul 19–20.
32. Oxman DA, Chow JK, Frendl G, Hadley S, HersHKovitz S, Ireland P, et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is *Candida* speciation predictive of the susceptibility pattern? *J Antimicrob Chemother*. 2010;65:1460–5. <https://doi.org/10.1093/jac/dkq136>
33. Shorr AF, Lazarus DR, Sherner JH, Jackson WL, Morrel M, Fraser VJ, et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. *Crit Care Med*. 2007;35:1077–83. <https://doi.org/10.1097/01.CCM.0000259379.97694.00>
34. Blanchard E, Lortholary O, Boukris-Sitbon K, Desnos-Ollivier M, Dromer F, Guillemot D; French Mycosis Study Group. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in *Candida* spp.: a case-control study in Paris, France. *Antimicrob Agents Chemother*. 2011;55:5358–61. <https://doi.org/10.1128/AAC.00690-11>
35. Husna I. Changing distribution of *Candida* species causing bloodstream infections in SA 2019 to 2021. National Institute for Communicable Diseases. 2022 [cited 2024 Sep 13]. <http://www.nicd.ac.za/wp-content/uploads/2022/08/Changing-distribution-of-Candida-species-causing-bloodstream-infections-in-SA-2019-to-2021.pdf>
36. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in Fks1p in *Candida parapsilosis*, *Candida orthopsilosis*, and *Candida metapsilosis* accounts for reduced echinocandin susceptibility. *Antimicrob Agents Chemother*. 2008;52:2305–12. <https://doi.org/10.1128/AAC.00262-08>
37. van Schalkwyk E, Iyaloo S, Naicker SD, Maphanga TG, Mpembe RS, Zulu TG, et al. Large outbreaks of fungal and bacterial bloodstream infections in a neonatal unit, South Africa, 2012–2016. *Emerg Infect Dis*. 2018;24:1204–12. <https://doi.org/10.3201/eid2407.171087>
38. Manzoni P, Leonessa M, Galletto P, Latino MA, Arisio R, Maule M, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant *Candida* subspecies. *Pediatr Infect Dis J*. 2008;27:731–7. <https://doi.org/10.1097/INF.0b013e318170bb0c>
39. da Silva EM, Sciuniti Benites Mansano E, de Souza Bonfim-Mendonça P, Olegário R, Tobaldini-Valério F, Fiorini A, et al. High colonization by *Candida parapsilosis* sensu stricto on hands and surfaces in an adult intensive care unit. *J Mycol Med*. 2021;31:101110. <https://doi.org/10.1016/j.mycmed.2020.101110>
40. Thomaz DY, de Almeida JN Jr, Sejas ONE, Del Negro GMB, Carvalho GOMH, Gímenes VMF, et al. Environmental clonal spread of azole-resistant *Candida parapsilosis* with Erg11-Y132F mutation causing a large candidemia outbreak in a Brazilian cancer referral center. *J Fungi (Basel)*. 2021;7:259. <https://doi.org/10.3390/jof7040259>
41. Magobo RE, Lockhart SR, Govender NP. Fluconazole-resistant *Candida parapsilosis* strains with a Y132F substitution in the *ERG11* gene causing invasive infections in a neonatal unit, South Africa. *Mycoses*. 2020;63:471–7. <https://doi.org/10.1111/myc.13070>
42. Daneshnia F, Hilmioglu-Polat S, Ilkit M, Fuentes D, Lombardi L, Binder U, et al. Whole-genome sequencing confirms a persistent candidaemia clonal outbreak due to multidrug-resistant *Candida parapsilosis*. *J Antimicrob Chemother*. 2023;78:1488–94. <https://doi.org/10.1093/jac/dkad112>
43. The National Department of Health. Standard treatment guidelines and essential medicines list for South Africa. Paediatric hospital level 2023 edition. Chapter 8.6. Candidiasis [cited 2025 Jun 30]. <https://www.health.gov.za/wp-content/uploads/2025/06/Paediatric-STGs-and-EML-2023-Edition-Updated-May-2025.pdf>
44. Arendrup MC, Sulim S, Holm A, Nielsen L, Nielsen SD, Knudsen JD, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. *J Clin Microbiol*. 2011;49:3300–8. <https://doi.org/10.1128/JCM.00179-11>

---

Address for correspondence: Nelesh P. Govender, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Rd, Parktown 2193, Johannesburg, South Africa; email: nelesh.govender@wits.ac.za